Skip to Content Skip to Search

Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

  • FY 2022-2026 figures are as at 09/06/2022
Please select...
£m (unless stated) 2022 2023 2024 2025 2026 2022-2026 n=
Turnover - Specialty ex pandemic solutions 8,202 9,201 10,222 11,168 11,989 12
Turnover - General Medicines 9,428 9,310 9,208 9,089 8,981 12
Turnover - Vaccines ex pandemic solutions 7,508 8,270 9,115 9,970 10,586 12
Turnover - New GSK excluding pandemic solutions 25,138 26,781 28,545 30,227 31,557 12
Turnover - New GSK pandemic solutions 1,453 210 121 84 63 12
Turnover - New GSK 26,591 26,990 28,666 30,311 31,620 12
Turnover - Consumer Healthcare 10,239 10,677 11,092 11,515 11,950 12
Turnover -  Group 36,830 37,668 39,757 41,826 43,570 12
Cost of sales (11,552) (11,273) (11,731) (12,213) (12,634) 12
Selling, general and administration (10,981) (11,266) (11,606) (11,922) (12,244) 12
Research and Development (5,087) (5,314) (5,580) (5,858) (6,053) 12
Royalty income 608 676 454 490 516 12
Operating profit 9,819 10,490 11,295 12,323 13,155 12
Net finance costs (778) (759) (722) (676) (641) 12
Associates 5 4 4 5 5 12
Profit before tax 9,045 9,735 10,578 11,651 12,519 12
Taxation (1,625) (1,829) (2,006) (2,219) (2,383) 12
Tax Rate 18.0% 18.8% 19.0% 19.0% 19.0% 12
Profit after tax  7,420 7,906 8,572 9,432 10,135 12
Minority interests (1,188) (1,255) (1,324) (1,389) (1,447) 12
Profit attributable to shareholders 6,232 6,651 7,248 8,043 8,688 12
WANS (m) 5,025 5,046 5,067 5,084 5,096 12
Earnings per share (p) 124.0 131.8 143.1 158.2 170.5 12
Dividend per share (p) 52.8 54.7 56.9 59.3 61.4 11
Free Cash Flow 4,968 5,784 6,301 7,028 7,499 9
Net Debt (19,357) (16,319) (12,802) (8,666) (4,294) 10
             
USD / GBP 1.31 1.30 1.30 1.30 1.30 12
EUR / GBP 1.19 1.19 1.19 1.19 1.19 12
JPY / GBP 159 161 161 161 161 9

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Redburn, UBS, Wolfe Research.

Citi, Goldman Sachs, Guggenheim and Morgan Stanley are currently restricted.

Turnover £m 2022 2023 2024 2025 2026 2022-2026 n=
             
Tivicay 1,278 1,179 1,090 1,007 930 12
Triumeq 1,662 1,477 1,312 1,189 1,082 12
Juluca 583 625 661 692 717 12
Dovato 1,189 1,496 1,742 1,929 2,085 12
Dolutegravir based regimens 4,711 4,777 4,805 4,817 4,814 12
Cabenuva 214 413 619 813 961 12
Apretude 42 126 246 361 463 12
Cabotegravir +/- rilpivirine 256 539 865 1,174 1,424 12
Rukobia 92 131 165 191 214 12
Other HIV 103 89 80 77 83 n/a
HIV 5,162 5,537 5,915 6,259 6,535 12
             
Benlysta 1,051 1,170 1,268 1,279 1,248 12
Nucala 1,330 1,457 1,556 1,630 1,679 12
             
Zejula 471 575 670 758 841 12
Blenrep 138 232 323 407 483 12
Jemperli 28 63 97 132 161 12
             
daprodustat 17 118 216 304 366 11
             
Specialty Medicines ex pandemic solutions 8,202 9,201 10,222 11,168 11,989 12
             
Xevudy 1,414 191 98 69 52 12
             
Specialty Medicines 9,617 9,392 10,319 11,237 12,041 12

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Redburn, UBS, Wolfe Research.

Citi, Goldman Sachs, Guggenheim and Morgan Stanley are currently restricted.

Turnover £m 2022 2023 2024 2025 2026 2022-2026 n=
Bexsero 731 778 805 826 847 12
Menveo 302 315 322 329 332 12
Other Meningitis 30 30 30 30 29 6
Meningitis 1,063 1,123 1,157 1,185 1,208 12
Fluarix/Flulaval 715 739 758 778 798 12
Shingrix 2,608 3,135 3,652 4,123 4,518 12
Boostrix 575 586 596 606 615 12
Cervarix 134 135 136 137 138 11
Hepatitis 526 560 579 596 611 12
Infanrix, Pediarix 568 566 567 569 572 12
Rotarix 565 579 592 605 616 12
Synflorix 353 352 349 342 336 12
Established Vaccines 3,121 3,189 3,233 3,273 3,303 12
Vaccines ex pandemic solutions 7,508 8,270 9,115 9,970 10,586 12
Pandemic solutions 38 19 23 16 12 12
Vaccines 7,546 8,288 9,138 9,985 10,598 12

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Redburn, UBS, Wolfe Research.

Citi, Goldman Sachs, Guggenheim and Morgan Stanley are currently restricted.

Turnover £m 2022 2023 2024 2025 2026 2022-2026 n=
Anoro 505 514 520 521 522 12
Arnuity 53 55 55 56 57 12
Avamys/Veramyst 294 265 242 226 213 11
Flixotide/Flovent 430 397 375 353 332 12
Incruse 210 215 221 224 229 12
Relvar/Breo 1,086 1,075 1,070 1,059 1,051 12
Seretide/Advair 1,184 1,058 956 863 790 12
Trelegy 1,622 1,912 2,133 2,303 2,437 12
Ventolin 680 628 597 568 542 12
Respiratory 6,176 6,218 6,259 6,257 6,249 12
Other General Medicines 3,252 3,092 2,949 2,833 2,732 12
             
General Medicines 9,428 9,310 9,208 9,089 8,981 12

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Redburn, UBS, Wolfe Research.

Citi, Goldman Sachs, Guggenheim and Morgan Stanley are currently restricted.

Turnover £m 2022 2023 2024 2025 2026 2022-2026 n=
Oral Care 2,917 3,058 3,189 3,321 3,458 10
Pain Relief 2,457 2,562 2,656 2,754 2,855 10
Respiratory health 1,305 1,350 1,389 1,430 1,472 10
VMS 1,639 1,711 1,783 1,856 1,936 10
Digestive Health and other 1,921 1,996 2,075 2,154 2,229 10
Consumer Health 10,239 10,677 11,092 11,515 11,950 12

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Redburn, UBS, Wolfe Research.

Citi, Goldman Sachs, Guggenheim and Morgan Stanley are currently restricted.

Back to top